Literature DB >> 11233850

Candidemia before and during the fluconazole era: prevalence, type of species and approach to treatment in a tertiary care community hospital.

J Baran1, B Muckatira, R Khatib.   

Abstract

The characteristics of candidemia before and after the introduction of fluconazole were compared at our institution. In the pre-fluconazole era (1986-89), the incidence of candidemia rose from 0.02% to 13% over the course of 4 y. Candida albicans accounted for 44/66 isolates (67%) and C. glabrata and C. parapsilosis were the predominant non-albicans species (9% each). In one-third of cases antifungal therapy was not given and the overall mortality rate was 55%. During the fluconazole era (1994-97), the incidence of candidemia remained constant between 1994 and 1996 at 0.09-0.11% and dropped to 0.06% in 1997. Bloodstream infection associated with neutropenia increased significantly but only accounted for 13% of cases; antifungal prophylaxis was not employed. The isolation of C. albicans decreased (n = 49; 50%) whereas isolation of both C. parapsilosis (n = 23; 24%) and C. tropicalis (n = 16; 16%) increased. The vast majority of patients received antifungal therapy and the overall mortality rate was 39%. These findings show that the incidence of candidemia rose steadily prior to the fluconazole era and then stabilized in spite of a shift towards non-albicans species. When candidemia was encountered in the fluconazole era, it was rare not to give antifungal treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11233850     DOI: 10.1080/003655401750065544

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  10 in total

1.  The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice.

Authors:  Brad J Spellberg; Ashraf S Ibrahim; Valentina Avenissian; Scott G Filler; Carter L Myers; Yue Fu; John E Edwards
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 2.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

3.  Fecal fungal flora of pediatric healthy volunteers and immunosuppressed patients.

Authors:  H Agirbasli; S A Keceli Ozcan; Gündüz Gedikoğlu
Journal:  Mycopathologia       Date:  2005-06       Impact factor: 2.574

4.  Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

Review 5.  Candida parapsilosis, an emerging fungal pathogen.

Authors:  David Trofa; Attila Gácser; Joshua D Nosanchuk
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

6.  Non-albicans Candida is the most common cause of candidemia in pediatric cancer patients.

Authors:  C A Mullen; H Abd El-Baki; H Samir; J J Tarrand; K V Rolston
Journal:  Support Care Cancer       Date:  2003-03-11       Impact factor: 3.603

7.  Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir.

Authors:  Benoite Kaeser; Hagen Zandt; Fabrice Bour; Elke Zwanziger; Christophe Schmitt; Xiaoping Zhang
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

8.  Relationship of fluconazole prophylaxis with fungal microbiology in hospitalized intra-abdominal surgery patients: a descriptive cohort study.

Authors:  Marya Zilberberg; Hsing-Ting Yu; Paresh Chaudhari; Matthew F Emons; Nikhil Khandelwal; Andrew F Shorr
Journal:  Crit Care       Date:  2014-10-29       Impact factor: 9.097

Review 9.  Continuing Shifts in Epidemiology and Antifungal Susceptibility Highlight the Need for Improved Disease Management of Invasive Candidiasis.

Authors:  Ben Y Parslow; Christopher R Thornton
Journal:  Microorganisms       Date:  2022-06-13

10.  Posaconazole in the management of refractory invasive fungal infections.

Authors:  Stefan Langner; Philipp B Staber; Peter Neumeister
Journal:  Ther Clin Risk Manag       Date:  2008-08       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.